Sight Sciences Inc (SGHT)

$4.3

+0.08

(+1.9%)

Market is closed - opens 8 PM, 23 Feb 2024

Insights on Sight Sciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 23.47M → 20.00M (in $), with an average decrease of 14.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -17.06M → -13.03M (in $), with an average increase of 14.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.1% return, outperforming this stock by 103.3%

Performance

  • $4.09
    $4.31
    $4.30
    downward going graph

    4.88%

    Downside

    Day's Volatility :4.99%

    Upside

    0.12%

    downward going graph
  • $1.04
    $11.66
    $4.30
    downward going graph

    75.81%

    Downside

    52 Weeks Volatility :91.08%

    Upside

    63.12%

    downward going graph

Returns

PeriodSight Sciences IncSector (Health Care)Index (Russel 2000)
3 Months
68.8%
11.5%
0.0%
6 Months
-40.06%
9.2%
0.0%
1 Year
-62.15%
12.0%
-6.6%
3 Years
-87.4%
27.4%
-21.4%

Highlights

Market Capitalization
202.3M
Book Value
$2.61
Earnings Per Share (EPS)
-1.27
Wall Street Target Price
5.13
Profit Margin
-74.55%
Operating Margin TTM
-67.03%
Return On Assets TTM
-19.66%
Return On Equity TTM
-41.17%
Revenue TTM
82.8M
Revenue Per Share TTM
1.71
Quarterly Revenue Growth YOY
7.1%
Gross Profit TTM
59.0M
EBITDA
-62.6M
Diluted Eps TTM
-1.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.24
EPS Estimate Next Year
-1.01
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    50%Buy
    50%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Sight Sciences Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
9
Hold
6
6
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 19.3%

Current $4.30
Target $5.13

Company Financials

FY18Y/Y Change
Revenue
7.5M
-
Net Income
-14.3M
-
Net Profit Margin
-189.77%
-
FY19Y/Y Change
Revenue
23.3M
↑ 210.07%
Net Income
-25.9M
↑ 81.03%
Net Profit Margin
-110.8%
↑ 78.97%
FY20Y/Y Change
Revenue
27.6M
↑ 18.38%
Net Income
-34.7M
↑ 34.11%
Net Profit Margin
-125.52%
↓ 14.72%
FY21Y/Y Change
Revenue
49.0M
↑ 77.12%
Net Income
-63.0M
↑ 81.48%
Net Profit Margin
-128.61%
↓ 3.09%
FY22Y/Y Change
Revenue
71.3M
↑ 45.7%
Net Income
-86.2M
↑ 36.98%
Net Profit Margin
-120.9%
↑ 7.71%
FY23Y/Y Change
Revenue
82.8M
↑ 16.15%
Net Income
-61.8M
↓ 28.38%
Net Profit Margin
-74.55%
↑ 46.35%
Q2 FY22Q/Q Change
Revenue
17.2M
↑ 15.78%
Net Income
-23.8M
↑ 2.49%
Net Profit Margin
-138.39%
↑ 17.94%
Q3 FY22Q/Q Change
Revenue
18.7M
↑ 8.4%
Net Income
-22.2M
↓ 6.77%
Net Profit Margin
-119.02%
↑ 19.37%
Q4 FY22Q/Q Change
Revenue
20.5M
↑ 9.99%
Net Income
-16.9M
↓ 23.94%
Net Profit Margin
-82.3%
↑ 36.72%
Q1 FY23Q/Q Change
Revenue
18.8M
↓ 8.37%
Net Income
-17.1M
↑ 0.95%
Net Profit Margin
-90.67%
↓ 8.37%
Q2 FY23Q/Q Change
Revenue
23.5M
↑ 24.69%
Net Income
-14.8M
↓ 13.55%
Net Profit Margin
-62.86%
↑ 27.81%
Q3 FY23Q/Q Change
Revenue
20.0M
↓ 14.75%
Net Income
-13.0M
↓ 11.65%
Net Profit Margin
-65.15%
↓ 2.29%
FY18Y/Y Change
Total Assets
8.1M
-
Total Liabilities
37.1M
-
FY19Y/Y Change
Total Assets
30.7M
↑ 279.8%
Total Liabilities
85.4M
↑ 130.53%
FY20Y/Y Change
Total Assets
72.8M
↑ 136.84%
Total Liabilities
161.7M
↑ 89.24%
FY21Y/Y Change
Total Assets
280.2M
↑ 284.84%
Total Liabilities
48.1M
↓ 70.26%
FY22Y/Y Change
Total Assets
213.1M
↓ 23.95%
Total Liabilities
53.0M
↑ 10.23%
Q2 FY22Q/Q Change
Total Assets
240.7M
↓ 6.9%
Total Liabilities
49.0M
↑ 4.95%
Q3 FY22Q/Q Change
Total Assets
225.2M
↓ 6.44%
Total Liabilities
52.3M
↑ 6.75%
Q4 FY22Q/Q Change
Total Assets
213.1M
↓ 5.4%
Total Liabilities
53.0M
↑ 1.34%
Q1 FY23Q/Q Change
Total Assets
196.6M
↓ 7.71%
Total Liabilities
50.3M
↓ 5.16%
Q2 FY23Q/Q Change
Total Assets
185.3M
↓ 5.77%
Total Liabilities
49.2M
↓ 2.2%
Q3 FY23Q/Q Change
Total Assets
176.6M
↓ 4.67%
Total Liabilities
49.6M
↑ 0.84%
FY18Y/Y Change
Operating Cash Flow
-14.5M
-
Investing Cash Flow
-570.0K
-
Financing Cash Flow
12.2M
-
FY19Y/Y Change
Operating Cash Flow
-25.0M
↑ 72.69%
Investing Cash Flow
-672.0K
↑ 17.89%
Financing Cash Flow
42.7M
↑ 249.62%
FY20Y/Y Change
Operating Cash Flow
-32.2M
↑ 28.71%
Investing Cash Flow
-953.0K
↑ 41.82%
Financing Cash Flow
73.4M
↑ 72.04%
FY21Y/Y Change
Operating Cash Flow
-52.5M
↑ 63.3%
Investing Cash Flow
-813.0K
↓ 14.69%
Financing Cash Flow
252.5M
↑ 244.04%
FY22Y/Y Change
Operating Cash Flow
-76.0M
↑ 44.59%
Investing Cash Flow
-970.0K
↑ 19.31%
Financing Cash Flow
1.2M
↓ 99.51%
Q2 FY22Q/Q Change
Operating Cash Flow
-18.3M
↓ 16.67%
Investing Cash Flow
-342.0K
↑ 50.66%
Financing Cash Flow
158.0K
↑ 71.74%
Q3 FY22Q/Q Change
Operating Cash Flow
-20.2M
↑ 10.31%
Investing Cash Flow
-272.0K
↓ 20.47%
Financing Cash Flow
186.0K
↑ 17.72%
Q4 FY22Q/Q Change
Operating Cash Flow
-15.5M
↓ 23.23%
Investing Cash Flow
-129.0K
↓ 52.57%
Financing Cash Flow
812.0K
↑ 336.56%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.4M
↑ 12.13%
Investing Cash Flow
-126.0K
↓ 2.33%
Financing Cash Flow
-156.0K
↓ 119.21%
Q2 FY23Q/Q Change
Operating Cash Flow
-13.5M
↓ 22.4%
Investing Cash Flow
-97.0K
↓ 23.02%
Financing Cash Flow
766.0K
↓ 591.03%

Technicals Summary

Sell

Neutral

Buy

Sight Sciences Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sight Sciences Inc
Sight Sciences Inc
-28.35%
-40.06%
-62.15%
-87.4%
-87.4%
Stryker Corporation
Stryker Corporation
10.95%
26.17%
32.83%
42.94%
84.22%
Boston Scientific Corp.
Boston Scientific Corp.
8.25%
30.43%
41.06%
67.73%
62.27%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
15.29%
14.06%
14.87%
3.97%
50.69%
Abbott Laboratories
Abbott Laboratories
3.22%
12.1%
14.78%
-3.82%
54.83%
Medtronic Plc
Medtronic Plc
-0.66%
2.6%
0.94%
-25.79%
-8.39%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sight Sciences Inc
Sight Sciences Inc
NA
NA
NA
-1.24
-0.41
-0.2
NA
2.61
Stryker Corporation
Stryker Corporation
42.19
42.19
3.22
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
61.89
61.89
2.06
2.25
0.09
0.04
NA
12.89
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.78
37.78
5.27
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
35.89
35.89
26.98
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
27.87
27.87
1.61
5.16
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sight Sciences Inc
Sight Sciences Inc
Buy
$202.3M
-87.4%
NA
-74.55%
Stryker Corporation
Stryker Corporation
Buy
$132.4B
84.22%
42.19
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$97.0B
62.27%
61.89
11.19%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.3B
50.69%
37.78
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$202.4B
54.83%
35.89
14.27%
Medtronic Plc
Medtronic Plc
Buy
$114.2B
-8.39%
27.87
12.84%

Institutional Holdings

  • KCK Ltd

    9.53%
  • BlackRock Inc

    3.38%
  • Jackson Square Partners, LLC

    3.34%
  • Vanguard Group Inc

    2.89%
  • JPMorgan Chase & Co

    2.15%
  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    1.47%

Corporate Announcements

  • Sight Sciences Inc Earnings

    Sight Sciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

sight sciences, inc. is a medical devices company based out of menlo park, california, united states.

Organization
Sight Sciences Inc
Employees
250
CEO
Mr. Paul Badawi
Industry
Healthcare

FAQs